Drug Type Fc fusion protein, Biosimilar |
Synonyms Dulaglutide Biosimilar (Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.), 度拉糖肽生物类似药(九源基因), JY 05 + [1] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Preclinical | China | 28 Mar 2024 |






